Top

Published in:

Open Access 01-12-2012 | Original investigation

The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults

Authors: Feng-Hsiang Chiu, Chung Hsun Chuang, Wen-Cheng Li, Yi-Ming Weng, Wen-Chih Fann, Hsiang-Yun Lo, Cheng Sun, Shih-Hao Wang

Published in: Cardiovascular Diabetology | Issue 1/2012

Abstract

Background

Serum C-reactive protein (CRP) and leptin levels have been independently associated with the cardiovascular risk factors. The aim of the present study was to determine if their serum levels were associated with cardiovascular risk factors or metabolic syndrome as well as their correlation in the Taiwanese population.

Methods

This retrospective study included 999 subjects (> 18 y), who underwent a physical examination in Chang-Gung Memorial Hospital-Linkou and Chiayi in Taiwan. The associations between CRP and/or leptin levels and cardiovascular risk factors and metabolic syndrome were determined using independent two sample t-tests to detect gender differences and chi-square tests to evaluate differences in frequencies. To compare the means of the variables measured among the four groups (high and low leptin and high and low CRP), analysis of variance (ANOVA) was used.

Results

Both CRP and leptin levels were independently associated with several cardiovascular risk factors, including diabetes, hypercholesterolemia and metabolic syndrome in both men and women (P < 0.05). In addition, a positive correlation between leptin and CRP levels was observed in both genders. Both high-CRP and high-leptin were associated with high blood glucose, waist circumference and serum triglyceride. Whereas increased metabolic syndrome incidence was observed in males with elevated leptin regardless of CRP levels, females with elevated CRP or leptin had increased incidence of metabolic syndrome.

Conclusion

Both leptin and CRP levels were associated with cardiovascular risk factors as well as metabolic syndrome score in both men and women although gender-specific differences were observed. Thus, CRP and leptin may represent useful biomarkers for predicting the onset of cardiovascular disease or metabolic syndrome in Taiwanese adults.

Trial registration

IRB/CGMH 100-3514B

Available only for authorised users

Jialal I, Devaraj S: Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol. 2003, 91: 200-202. 10.1016/S0002-9149(02)03110-7.CrossRefPubMed

Ridker M, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003, 107: 391-397. 10.1161/01.CIR.0000055014.62083.05.CrossRefPubMed

Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study. Circulation. 1999, 99: 237-242. 10.1161/01.CIR.99.2.237.CrossRefPubMed

Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive protein to cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997, 17: 1112-1121.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999, 282: 2131-213. 10.1001/jama.282.22.2131.CrossRefPubMed

Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004, 110: 380-385. 10.1161/01.CIR.0000136581.59584.0E.CrossRefPubMed

Dowidar NL, Dejong CHC, Fearon KCH, Garden OJ, Ross JA: Effects of leptin on isolated human hepatocyte C reactive protein production. Eur J Gastroenterol Hepatol. 2000, 12: A18

Mantzoros CS: The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999, 130: 671-680.CrossRefPubMed

Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995, 269: 543-546. 10.1126/science.7624777.CrossRefPubMed

10.

Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, Halsall I, O’Rahilly S, Wareham NJ: Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res. 2005, 13: 1476-1484. 10.1038/oby.2005.178.CrossRefPubMed

11.

Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001, 104: 3052-3056. 10.1161/hc5001.101061.CrossRefPubMed

12.

Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004, 92: 347-355. 10.1079/BJN20041213.CrossRefPubMed

13.

Yanagawa T, Taniguchi A, Fukushima M, Nakai Y, Nagasaka S, Ohgushi M, Matsumotoe K, Kuroea A, Ohyaa M, Seinoa Y: Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2007, 75: 2-6. 10.1016/j.diabres.2006.04.019.CrossRefPubMed

14.

Kazumi T, Kawaguchi A, Hirano T, Yoshino G: C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism. 2003, 52: 1113-1116. 10.1016/S0026-0495(03)00184-7.CrossRefPubMed

15.

Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, Berger PB, Somers VK: Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004, 109: 2181-2185. 10.1161/01.CIR.0000127960.28627.75.CrossRefPubMed

16.

Ble A, Windham BG, Bandinelli S, Taub DD, Volpato S, Bartali B, Tracy RP, Guralnik JM, Ferrucci L: Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). Am J Cardiol. 2005, 96: 991-995. 10.1016/j.amjcard.2005.05.058.CrossRefPubMed

17.

Viikari LA, Huupponen RK, Viikari JS, Marniemi J, Eklund C, Hurme M, Lhetimaki T, Kivimaki M, Raitakari OT: Relationship between leptin and C-reactive protein in young Finnish adults. J Clin Endocrinol Metab. 2007, 92: 4753-4758. 10.1210/jc.2007-0103.CrossRefPubMed

18.

Ukkola O, Kesäniemi YA: Leptin and high-sensitivity C-reactive protein and their interaction in the metabolic syndrome in middle-aged subjects. Metabolism. 2007, 56: 1221-1227. 10.1016/j.metabol.2007.04.019.CrossRefPubMed

19.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2.CrossRefPubMed

20.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003, 289: 2560-2572. 10.1001/jama.289.19.2560.CrossRefPubMed

21.

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997, 20: 1183-1197.

22.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.

23.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Fernando Costa: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed

24.

Tan CE, Ma S, Wai D, Chew Sk, Tai ES: Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians. Diabetes Care. 2004, 27: 1182-1186. 10.2337/diacare.27.5.1182.CrossRefPubMed

25.

Xu L, Jiang CQ, Lam TH, Lin JM, Yue XJ, Cheng KK, Liu B, Jin YL, Zhang WS, Thomas GN: The Metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance:Guangzhou Biobank Cohort Study-CVD. Clin Endocrinol. 2010, 73: 181-188.

26.

Li WC, Hsiao KY, Chen IC, Chang YC, Wang SH, Wu KH: Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol. 2011, 10: 36-10.1186/1475-2840-10-36.PubMedCentralCrossRefPubMed

27.

Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M: Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997, 46: 313-316. 10.2337/diabetes.46.2.313.CrossRefPubMed

28.

Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw ID: Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord. 1999, 23: 29-36. 10.1038/sj.ijo.0800792.CrossRefPubMed

29.

Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 2000, 98: 531-535. 10.1042/CS20000013.CrossRef

30.

Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J. 1990, 265: 621-636.PubMedCentralCrossRefPubMed

31.

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997, 82: 4196-4200. 10.1210/jc.82.12.4196.PubMed

32.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995, 95: 2409-2415. 10.1172/JCI117936.PubMedCentralCrossRefPubMed

33.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.PubMedCentralCrossRefPubMed

34.

Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 1997, 100: 2777-2782. 10.1172/JCI119824.PubMedCentralCrossRefPubMed

35.

Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK: Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab. 2004, 89: 5577-5582. 10.1210/jc.2004-0603.CrossRefPubMed

36.

Santos-Alvarez J, Goberna R, Sánchez-Margalet V: Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999, 194: 6-11. 10.1006/cimm.1999.1490.CrossRefPubMed

37.

Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, Lai CF, Tartaglia LA: The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A. 1996, 93: 8374-8378. 10.1073/pnas.93.16.8374.PubMedCentralCrossRefPubMed

38.

Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ: Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006, 12: 425-432. 10.1038/nm1372.CrossRefPubMed

39.

40.

Shimizu H, Oh-I S, Okada S, Mori M: Leptin resistance and obesity. Endocr J. 2007, 54: 17-2. 10.1507/endocrj.KR-85.CrossRefPubMed

41.

Sung KC, Seo MH, Rhee EJ, Wilson AM: Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol. 2011, 10: 108-10.1186/1475-2840-10-108.PubMedCentralCrossRefPubMed

42.

Chien KL, Lin HJ, Lee BC, Hsu HC, Chen MF: Prediction model for high glycated hemoglobin concentration among ethnic Chinese in Taiwan. Cardiovasc Diabetol. 2010, 9: 59-10.1186/1475-2840-9-59.PubMedCentralCrossRefPubMed

43.

Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, Joseph L, Hess DT, Apovian CM, Vita JA, Gokce N: Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol. 2011, 58: 232-237. 10.1016/j.jacc.2011.01.051.PubMedCentralCrossRefPubMed

Title: The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults
Authors: Feng-Hsiang Chiu
Chung Hsun Chuang
Wen-Cheng Li
Yi-Ming Weng
Wen-Chih Fann
Hsiang-Yun Lo
Cheng Sun
Shih-Hao Wang
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-11-40

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The association of leptin and C-reactive protein with the cardiovascular risk factors and metabolic syndrome score in Taiwanese adults

Abstract

Background

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2012

Regional evidence of modulation of cardiac adiponectin level in dilated cardiomyopathy: pilot study in a porcine animal model

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Association between body size and blood pressure in children from different ethnic origins

Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus

Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults

Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page